The Egyptian Drug Authority (EDA) celebrated today the launch of the scientific content of the fifth edition of the Egyptian Pharmacopoeia, highlighting this landmark achievement accomplished by the Authority.
The event was attended by Dr. Ali Al-Ghamrawy, Chairman of the Egyptian Drug Authority; Prof. Dr. Ayman El-Khatib, Vice Chairman of the EDA and Chairman of the Permanent Committee for Drafting the Egyptian Pharmacopoeia; Prof. Dr. Mohamed Awad Tag El-Din, Advisor to the President of the Republic for Health and Prevention Affairs; members of the Permanent Committee responsible for drafting the Egyptian Pharmacopoeia; representatives of the United States Pharmacopeia (USP), the Senate Health Committee, the World Health Organization (WHO), the Chamber of Pharmaceutical Industries, the Pharmaceutical Division of the Federation of Egyptian Chambers of Commerce, as well as Egyptian and international pharmaceutical companies and senior officials of the Egyptian Drug Authority.
The celebration coincided with the issuance of a decision by the Chairman of the Egyptian Drug Authority approving the implementation of the Egyptian Pharmacopoeia – Fifth Edition (2024) and its subsequent updates as an official reference for the registration of pharmaceutical and biological products in the Arab Republic of Egypt.
The Egyptian Pharmacopoeia serves as an authoritative scientific reference for all matters related to medicines and pharmaceutical preparations. It includes essential medicinal products and their monographs, covering definitions, specifications, identification tests, purity tests, analytical methods, standardization procedures, and dosage information. Issued by the State through the competent pharmaceutical authority, the Pharmacopoeia is promulgated by a decision of the Egyptian Drug Authority and carries legal authority upon publication.
The Egyptian Pharmacopoeia aims to establish and strengthen a robust regulatory system aligned with international scientific references and regulatory frameworks by providing a comprehensive reference and governance framework for medicines and pharmaceutical preparations.
It is worth noting that the Authority established the Permanent Committee for Drafting the Egyptian Pharmacopoeia under the chairmanship of Prof. Dr. Ayman El-Khatib, Vice Chairman of the EDA. Since November 2020, the Committee has undertaken extensive efforts, including studying the structures, contents, and indexing methodologies of leading international pharmacopoeias; establishing specialized technical committees; digitalizing all preparation and follow-up procedures to incorporate the latest scientific and technological advancements; and fostering effective collaboration with representatives of international pharmacopoeias and relevant organizations. These efforts aim to establish clear and recognized reference standards governing the pharmaceutical sector and ensuring the safety, efficacy, and quality of medicines available to Egyptian patients.
These efforts culminated in the current edition of the Egyptian Pharmacopoeia following its review and approval by the EDA Board of Directors. The scientific content has been released in electronic format to facilitate continuous updates in the future. The Pharmacopoeia can be accessed through the dedicated mobile application and the Egyptian Pharmacopoeia database available on the official website of the Egyptian Drug Authority.
This milestone also coincides with the issuance of a dedicated regulatory guideline for the preparation of the Egyptian Pharmacopoeia, outlining all mechanisms and procedures governing the development of its scientific content and enabling effective monitoring, evaluation, and performance assessment.
Individuals interested in contributing to the activities of the Egyptian Pharmacopoeia are invited to complete the participation form available on the official website of the Egyptian Drug Authority and submit it via email to: